- Details
- From the Tulane Cancer Center, Kendra Harris, Chair of Radiation Oncology explains the process of preparing for treatment of Pluvicto™ (177Lu-PSMA-617). Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate...
|
- Details
- From the Tulane Cancer Center, Kendra Harris Chair of Radiation Oncology demonstrates the process of administering a dose of Pluvicto™ (177Lu-PSMA-617). Phillip Koo meets with the patient in a brief post-dose administration discussion. Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer...
|
- Details
- Drs Oliver Sartor and Kendra Harris join Phillip Koo to discuss the clinical implications and integration of Pluvicto™ into clinical practice and offer guidance to clinicians looking to implement this therapy in their clinics. Pluvicto™ (177Lu-PSMA-617) is the first FDA-approved targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: A. Olive...
|
- Details
- Chair of Radiation Oncology at Tulane University Cancer Center, Kendra Harris joins Phillip Koo to discuss radiation safety in regards to the recent approval of Pluvicto™, the first targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate Professor, Tulane Cancer Center, Tulane Unive...
|
- Details
- Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...
|
- Details
- Alicia Morgans is joined by Brian Gonzalez to discuss work he presented at GU ASCO 2022 on patient-reported quality of life metrics among men receiving prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study being discussed treated 50 patients, between 2015 to 2017, with up to 4 cycles of 177Lu-PSM...
|
- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...
|
- Details
- Phillip Koo is joined by Hossein Jadvar to discuss the Appropriate Use Criteria (AUC) for PSMA PET in prostate cancer. Dr. Jadvar, the first author of the publication, discusses the process of developing the AUC for PSMA PET in prostate cancer and reviews 11 clinical scenarios that may be encountered by ordering professionals when they want to consult the AUC for ordering their imaging. To guide r...
|
- Details
- Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...
|
